Endo International Plc shares slid almost 6% in premarket trade Thursday, after the company confirmed that its subsidiary, Endo Pharmaceuticals Inc., has received a grand jury subpoena from the U.S. Attorney’s Office for the Southern District of Florida, seeking information relating to products containing the opioid oxymorphone. The company said the subpoena is seeking documents including those produced in past or pending lawsuits, as well as those relating to safety and efficacy, overdoses, abuse/misuse and overprescribing, among other issues. The company said it intends to cooperate with the subpoena and any related investigation. The U.S. is currently in the midst of an opioid crisis stemming from widespread use of opioids as a pain medication. Endo shares have fallen 42% in the last 12 months, while the S&P 500 has gained 21%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News